"CD5 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
| Descriptor ID |
D018956
|
| MeSH Number(s) |
D23.050.301.264.051.101 D23.050.301.264.894.101 D23.101.100.150.101 D23.101.100.894.101
|
| Concept/Terms |
CD5 Antigens- CD5 Antigens
- T1 Antigen
- Leu-1 Antigen
- Leu 1 Antigen
- CD5 Antigen
- Antigen, CD5
- Antigens, CD5
|
Below are MeSH descriptors whose meaning is more general than "CD5 Antigens".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- CD5 Antigens [D23.050.301.264.051.101]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CD5 Antigens [D23.050.301.264.894.101]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- CD5 Antigens [D23.101.100.150.101]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CD5 Antigens [D23.101.100.894.101]
Below are MeSH descriptors whose meaning is more specific than "CD5 Antigens".
This graph shows the total number of publications written about "CD5 Antigens" by people in this website by year, and whether "CD5 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD5 Antigens" by people in Profiles.
-
Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998 Nov; 4(11):2691-700.